SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently seeing high volatility and intense community debate following an unexpected endorsement from Donald Trump, which has sparked speculation about institutional support and potential government contracts. Traders remain sharply divided, with bulls pointing to the company's defense-sector entrenchment while bears, including noted short-sellers, warn that its current valuation is unsustainable compared to emerging AI competition.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense retail and institutional interest as investors bet on its electro-optic polymer technology to solve data center bottlenecks in the AI infrastructure cycle. The community remains deeply divided, with bulls pointing to recent foundry integration partnerships and the potential for a major industry acquisition, while skeptics warn of pre-revenue risks and argue the current valuation is driven by speculative hype rather than fundamental milestones.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is seeing heightened attention following strong earnings results that highlighted robust performance in equities trading and investment banking. Market participants are actively discussing the bank's ability to navigate current market volatility, while debates continue regarding the broader financial sector's valuation and the impact of geopolitical and macroeconomic pressures on bank capital quality.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing extreme volatility driven by a major follow-on order for its 800G optical transceivers and intensifying speculation surrounding its role in hyperscale data center infrastructure. While the community is actively debating the company's valuation and reliance on a single key customer, bulls point to a massive production pipeline and long-term capacity expansion as structural catalysts for growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors express strong bullish sentiment ahead of key clinical trial milestones, including upcoming pancreatic cancer data and the finalization of U.S. recruitment for its skin cancer trial. The community is highlighting the company's clean balance sheet and recent analyst upgrades as evidence that the stock is significantly undervalued, with many users actively accumulating shares in anticipation of a potential breakout.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token surges on rumors of high-profile integrations and its expansion into Web3 entertainment. While some traders are celebrating massive gains and pointing to upcoming global event partnerships as long-term catalysts, others remain deeply skeptical, frequently labeling the project a speculative pump-and-dump scheme.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending following contract awards from the U.S. government for quantum materials and high-speed datacom, signaling a potential shift toward commercialization that has sparked intense debate among investors. The community is sharply divided, with bulls pointing to the company's proprietary III-V-on-silicon platform and low-float potential, while vocal criticsciting lack of foundry partnerships and limited revenueare actively challenging the company's valuation and long-term viability.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending following positive Phase 2/3 clinical trial results for its darovasertib combination therapy in metastatic uveal melanoma, which showed significant improvement in progression-free survival and led to an overnight surge in stock price. Investors are actively discussing the potential for accelerated FDA approval, institutional accumulation of shares, and the company's strong positioning as a clinical-stage oncology leader.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as traders debate whether it is currently in a resilient bull phase driven by AI capex demand or if it is a crowded, overextended bubble prone to a sharp mean reversion. While some market participants are aggressively positioning for a pullback, others are closely watching the sector's relative strength compared to lagging software stocks as a bellwether for broader market sentiment.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors digest detailed Phase 3 data for Axpaxli, with clinical presentations at the Macula Society and investor webcasts fueling intense speculation regarding a potential regulatory path or acquisition. While the community is debating the clinical nuances of the trial results, sentiment is buoyed by heavy institutional interest and the stock's recovery from recent volatility as participants position themselves ahead of further updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood buys $11 million of tumbling megacap tech stock

Cathie Wood, head of Ark Investment Management, frequently adjusts her tech positions. She buys more when stock prices fall and trims when they rally, locking in short-term gains while sticking to...

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Key PointsCEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026...

Beam Therapeutics (NASDAQ:BEAM) CEO Sells $739,317.24 in Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John Evans sold 30,078 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of...

Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price...

Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares of Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average...

Insider Selling: Beam Therapeutics (NASDAQ:BEAM) President Sells $290,289.80 in Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an...

John Evans Sells 30,078 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John Evans sold 30,078 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of...

SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM

SG Americas Securities LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 139.4% in the 4th quarter, according to the company in its most recent filing with the...

Beam Therapeutics (NASDAQ:BEAM) CEO John Evans Sells 25,000 Shares

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John Evans sold 25,000 shares of Beam Therapeutics stock in a transaction dated Monday, March 30th. The stock was sold at an average price...

Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells 25,000 Shares of Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the company's stock in a transaction on Monday, March 30th. The stock was sold at an average price of $22.37, for a total transaction of $559,250.00. Following the completion of the transaction, the chief...

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Current Price	$27.43
Prev Close	$26.33
Open	$26.49
Dividend Yield	0.00%
50-Day Moving Average	$26.34
Beta	1.84
Avg. Volume	2.15M
PE Ratio	-27.01

52-Week High	$36.44
52-Week Low	$15.35
Market Capitalization	$2.79B
EPS (Annual)	-$0.8088
Price to Book	2.25
Revenue Per Employee	$273,469.67

BEAM
Beam Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BEAM News

BEAMBeam Therapeutics Inc